Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: The overall response rate was 45% (95% confidence interval [CI], 36% to 54%) with ECF and 21% (95% CI, 13% to 29%) with FAMTX (P = .0002). Toxicity was tolerable and there were only three toxic deaths. The FAMTX regimen caused more hematologic toxicity and serious infections, but ECF caused more emesis and alopecia. The median survival duration was 8.9 months with ECF and 5.7 months with FAMTX (P = .0009); at 1 year, 36% (95% CI, 27% to 45%) of ECF and 21% (95% CI, 14% to 29%) of FAMTX patients were alive. The median failure-free survival duration was 7.4 months with ECF and 3.4 months with FAMTX (P = .00006). The global QL scores were better for ECF at 24 weeks, but the remaining QL data showed no differences between either arm of the study. Hospital-based cost analysis on a subset of patients was similar for each arm and translated into an increment cost of $975 per life-year gained. CONCLUSION: The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy. This regimen should now be considered the standard treatment for advanced esophagogastric cancer.
|
Authors | A Webb, D Cunningham, J H Scarffe, P Harper, A Norman, J K Joffe, M Hughes, J Mansi, M Findlay, A Hill, J Oates, M Nicolson, T Hickish, M O'Brien, T Iveson, M Watson, C Underhill, A Wardley, M Meehan |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 15
Issue 1
Pg. 261-7
(Jan 1997)
ISSN: 0732-183X [Print] United States |
PMID | 8996151
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Epirubicin
- Doxorubicin
- Cisplatin
- Fluorouracil
- Methotrexate
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(economics, therapeutic use)
- Carcinoma
(drug therapy)
- Cisplatin
(administration & dosage, economics)
- Costs and Cost Analysis
- Doxorubicin
(administration & dosage, economics)
- Drug Costs
- Epirubicin
(administration & dosage, economics)
- Esophageal Neoplasms
(drug therapy)
- Female
- Fluorouracil
(administration & dosage, economics)
- Humans
- Male
- Methotrexate
(administration & dosage, economics)
- Middle Aged
- Prospective Studies
- Quality of Life
- Stomach Neoplasms
(drug therapy)
- Survival Rate
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|